Pharmacogenomic study on anti-VEGF medicine in treatment of macular Neovascular diseases: a study protocol for a prospective observational study

BACKGROUND: Macular neovascular diseases can cause severe vision loss. A newly approved anti—VEGF drug Conbercept has shown good efficacy and safety in rigorous random controlled trials (RCT), however, it cannot fully reflect the clinical application of Conbercept in real world clinical practice. Mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Jing, Jin, Yinchen, Shen, Xia, Chen, Jing, Wang, Chong, Chen, Xun, Xu, Hengye, Huang, Kun, Liu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057085/
https://www.ncbi.nlm.nih.gov/pubmed/30041608
http://dx.doi.org/10.1186/s12886-018-0812-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057085/
https://www.ncbi.nlm.nih.gov/pubmed/30041608
http://dx.doi.org/10.1186/s12886-018-0812-4

Ejemplares similares